Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Hospira Beats Last Federal Test Case Over Breast Cancer Drug

Jan. 21, 2022, 7:58 PM

Hospira Inc. won dismissal of what would have been the last test trial in litigation linking the breast cancer drugs docetaxel and Taxotere to permanent hair loss, as a federal court in Louisiana said the suit was time-barred.

Audry Plaisance received Hospira’s docetaxel for several months, finishing treatment in March 2014. Her suit against Hospira and Hospira Worldwide LLC was filed in August 2018. She alleged the drugmakers didn’t adequately warn that hair loss, a common side effect of chemotherapy, could be permanent.

Hospira argued that Plaisance’s claims are barred by Louisiana’s one-year statute of limitations, which begins to run ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.